<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606109</url>
  </required_header>
  <id_info>
    <org_study_id>18-00535</org_study_id>
    <nct_id>NCT03606109</nct_id>
  </id_info>
  <brief_title>Reducing Hemarthrosis in High Tibial Osteotomy and Tibial Tubercle Osteotomy</brief_title>
  <official_title>Reducing Hemarthrosis in High Tibial Osteotomy and Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to see if giving intravenous tranexamic acid (TXA) to
      patients undergoing osteotomies will decrease bleeding in the joint and decrease post
      operative pain. In order to evaluate the effectiveness two groups: one group will have a high
      tibial osteotomy surgery and one group will have a tibial tubercle osteotomy surgery.
      Investigators will compare knee swelling, side effects, and pain scores at 24 hours, 48
      hours, and 7 days between both groups of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in blood loss between patients undergoing high tibial osteotomy (HTO) and tibial tubercle osteotomy (TTO)</measure>
    <time_frame>Day 1</time_frame>
    <description>estimated blood loss intra-operatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in post operative pain between patients undergoing HTO compared to patients undergoing TTO.</measure>
    <time_frame>7 Days</time_frame>
    <description>Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable) at 0.5, 1, 1.5, 2, 4, 6, 24, and 48 hours as well as 7 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in swelling between patients undergoing HTO compared to patients undergoing TTO.</measure>
    <time_frame>18 Months</time_frame>
    <description>Knee swelling postoperatively will be measured using the swelling ratio. The swelling ratio was defined as the circumference of the operative limb divided by the circumference of the contralateral limb</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteotomy</condition>
  <condition>High Tibial Osteotomy (HTO)</condition>
  <condition>Patello-femoral Ligament</condition>
  <arm_group>
    <arm_group_label>High tibial osteotomy (HTO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients indicated and scheduled for a high tibial osteotomy or tibial tubercle osteotomy with or without medial patello-femoral ligament reconstruction will be identified from faculty surgeon case logs at the NYU Langone Health, Langone Orthopedic Hospital Sports Medicine Division.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tibial tubercle osteotomy (TTO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients indicated and scheduled for a high tibial osteotomy or tibial tubercle osteotomy with or without medial patello-femoral ligament reconstruction will be identified from faculty surgeon case logs at the NYU Langone Health, Langone Orthopedic Hospital Sports Medicine Division.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Tranexamic Acid (TXA)</intervention_name>
    <description>Patients will be given 1 gram of intravenous tranexamic acid (TXA) before tourniquet inflation and 1 gram of IV TXA before closure of the incision.All patients will receive a standardized regimen of aspirin for DVT prophylaxis and Percocet for pain management, which is standard of care post-operative treatment.</description>
    <arm_group_label>High tibial osteotomy (HTO)</arm_group_label>
    <arm_group_label>Tibial tubercle osteotomy (TTO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing a high tibial osteotomy (HTO)

          -  Patients undergoing tibial tubercle osteotomy (TTO) with or without medial
             patello-femoral ligament (MPFL) reconstruction

        Exclusion Criteria:

          -  Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects,
             dementia, etc.)

          -  Younger than 18 years of age

          -  Older than 60 years of age

          -  Any patient considered a vulnerable subject

          -  Have bleeding or clotting disorder

          -  Preoperative anticoagulation therapy

          -  Abnormal coagulation profile

          -  Renal disorder or insufficiency

          -  Sickle cell disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Alaia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamali Thompson</last_name>
    <phone>646 501 8543</phone>
    <email>Kamali.Thompson@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamali Thompson</last_name>
      <phone>646-501-8543</phone>
      <email>Kamali.Thompson@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Alaia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid (TXA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemarthrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

